Evotec SE (EVO)

Market Cap	1.38B
Revenue (ttm)	851.94M
Net Income (ttm)	-223.72M
Shares Out	177.53M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,594
Open	3.940
Previous Close	4.170
Day's Range	3.940 - 3.980
52-Week Range	2.840 - 5.680
Beta	1.09
Analysts	Buy
Price Target	5.90 (+50.9%)
Earnings Date	May 6, 2025

About EVO

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio metabolic disorders; and animal and women health. The c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 4, 2021
• Employees: 4,740
• Stock Exchange: NASDAQ
• Ticker Symbol: EVO
• Website: https://www.evotec.com

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for EVO stock is "Buy." The 12-month stock price forecast is $5.9, which is an increase of 50.90% from the latest price.

Price Target

$5.9

(50.90% upside)

Analyst Consensus: Buy